# Upfront Combination Pulmonary Arterial Hypertension Therapy

> **NCT03809156** · PHASE4 · UNKNOWN · sponsor: **University of Calgary** · enrollment: 20 (estimated)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Riociguat Oral Product

## Key facts

- **NCT ID:** NCT03809156
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04-26
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809156, "Upfront Combination Pulmonary Arterial Hypertension Therapy". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03809156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*